U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C20H31NO
Molecular Weight 301.4662
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DERAMCICLANE

SMILES

[H][C@]12CC[C@](C)(C1(C)C)[C@@](C2)(OCCN(C)C)C3=CC=CC=C3

InChI

InChIKey=QOBGWWQAMAPULA-RLLQIKCJSA-N
InChI=1S/C20H31NO/c1-18(2)17-11-12-19(18,3)20(15-17,22-14-13-21(4)5)16-9-7-6-8-10-16/h6-10,17H,11-15H2,1-5H3/t17-,19-,20+/m1/s1

HIDE SMILES / InChI

Molecular Formula C20H31NO
Molecular Weight 301.4662
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Deramciclane is camphor derivative. It is an anxiolytic agent that binds with high affinity to 5-HT2A/2C receptor. Deramciclane showed significant evidence of efficacy for the treatment of generalized anxiety disorder in adult patients. A single dose of deramciclane was rapidly absorbed with peak plasma concentrations being reached after about 3 h. Deramciclane has a half-life of around 27 h. The most commonly reported adverse event was headache. In the in vitro studies deramciclane concentration-dependently inhibited NMDA evoked spreading depression.

Approval Year

PubMed

PubMed

TitleDatePubMed
8-OH-DPAT, but not deramciclane, antagonizes the anxiogenic-like action of paroxetine in an elevated plus-maze.
2001 Jan
Deramciclane (Egis).
2002 Feb
Studies of the side chain cleavage of deramciclane in rats with radiolabelled compounds.
2002 Mar
In vitro simulation of food effect on dissolution of deramciclane film-coated tablets and correlation with in vivo data in healthy volunteers.
2002 Mar
Pharmacokinetics of deramciclane, a novel anxiolytic agent, after intravenous and oral administration.
2003
Effect of the novel anxiolytic drug deramciclane on the pharmacokinetics and pharmacodynamics of the CYP3A4 probe drug buspirone.
2003 Dec
The effect of oil as a dietary component on in vitro dissolution of an acid-labile drug.
2003 Jul
Comparison of deramciclane to benzodiazepine agonists in behavioural activity of mice and in alcohol drinking of alcohol-preferring rats.
2004 Apr
Pharmacokinetics of deramciclane and N-desmethylderamciclane after single and repeated oral doses in healthy volunteers.
2004 Aug
Effect of the novel anxiolytic drug deramciclane on cytochrome P(450) 2D6 activity as measured by desipramine pharmacokinetics.
2004 Feb
Influence of food on the oral bioavailability of deramciclane from film-coated tablet in healthy male volunteers.
2004 Nov
Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study.
2005 Dec
Biotransformation of deramciclane in primary hepatocytes of rat, mouse, rabbit, dog, and human.
2005 Nov
Role of CYP2E1 in deramciclane metabolism.
2005 Nov
Comparison of the effects of deramciclane, ritanserin and buspirone on extracellular dopamine and its metabolites in striatum and nucleus accumbens of freely moving rats.
2008 Jan
Deramciclane improves object recognition in rats: potential role of NMDA receptors.
2010 Feb
Selective binding interactions of deramciclane to the genetic variants of human alpha(1)-acid glycoprotein.
2010 Mar
Patents

Patents

Sample Use Guides

60 mg/day
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Fri Dec 16 17:18:16 UTC 2022
Edited
by admin
on Fri Dec 16 17:18:16 UTC 2022
Record UNII
O5KFK61E74
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DERAMCICLANE
INN   MI   WHO-DD  
INN  
Official Name English
deramciclane [INN]
Common Name English
DERAMCICLANE [MI]
Common Name English
Deramciclane [WHO-DD]
Common Name English
Code System Code Type Description
INN
6838
Created by admin on Fri Dec 16 17:18:16 UTC 2022 , Edited by admin on Fri Dec 16 17:18:16 UTC 2022
PRIMARY
ChEMBL
CHEMBL2104698
Created by admin on Fri Dec 16 17:18:16 UTC 2022 , Edited by admin on Fri Dec 16 17:18:16 UTC 2022
PRIMARY
DRUG BANK
DB06512
Created by admin on Fri Dec 16 17:18:16 UTC 2022 , Edited by admin on Fri Dec 16 17:18:16 UTC 2022
PRIMARY
EPA CompTox
DTXSID10152862
Created by admin on Fri Dec 16 17:18:16 UTC 2022 , Edited by admin on Fri Dec 16 17:18:16 UTC 2022
PRIMARY
MESH
C060555
Created by admin on Fri Dec 16 17:18:16 UTC 2022 , Edited by admin on Fri Dec 16 17:18:16 UTC 2022
PRIMARY
NCI_THESAURUS
C174785
Created by admin on Fri Dec 16 17:18:16 UTC 2022 , Edited by admin on Fri Dec 16 17:18:16 UTC 2022
PRIMARY
PUBCHEM
119590
Created by admin on Fri Dec 16 17:18:16 UTC 2022 , Edited by admin on Fri Dec 16 17:18:16 UTC 2022
PRIMARY
EVMPD
SUB06986MIG
Created by admin on Fri Dec 16 17:18:16 UTC 2022 , Edited by admin on Fri Dec 16 17:18:16 UTC 2022
PRIMARY
MERCK INDEX
M4186
Created by admin on Fri Dec 16 17:18:16 UTC 2022 , Edited by admin on Fri Dec 16 17:18:16 UTC 2022
PRIMARY Merck Index
FDA UNII
O5KFK61E74
Created by admin on Fri Dec 16 17:18:16 UTC 2022 , Edited by admin on Fri Dec 16 17:18:16 UTC 2022
PRIMARY
CAS
120444-71-5
Created by admin on Fri Dec 16 17:18:16 UTC 2022 , Edited by admin on Fri Dec 16 17:18:16 UTC 2022
PRIMARY
WIKIPEDIA
DERAMCICLANE
Created by admin on Fri Dec 16 17:18:16 UTC 2022 , Edited by admin on Fri Dec 16 17:18:16 UTC 2022
PRIMARY
Related Record Type Details
TARGET->ANTAGONIST
TARGET->ANTAGONIST
Related Record Type Details
METABOLITE -> PARENT
IN VITRO
METABOLITE -> PARENT
IN VITRO
METABOLITE -> PARENT
IN VITRO
METABOLITE -> PARENT
IN VITRO
Related Record Type Details
ACTIVE MOIETY